{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:06:36Z","timestamp":1790802396797,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejca.2026.117014","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:45:43Z","timestamp":1787849143000},"page":"117014","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Local therapy to recurrent\/metastatic foci augments the benefit of immune checkpoint inhibitors in nasopharyngeal carcinoma"],"prefix":"10.1016","volume":"247","author":[{"given":"Xueqin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunying","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6407-3311","authenticated-orcid":false,"given":"Chaosu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueguan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7184-1101","authenticated-orcid":false,"given":"Xin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.117014_bib1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet (Lond Engl)"},{"key":"10.1016\/j.ejca.2026.117014_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2026.117014_bib3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ijc.32099","article-title":"Concurrent chemoradiotherapy with\/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial","volume":"145","author":"Li","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2026.117014_bib4","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.30566","article-title":"Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA\/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials","volume":"123","author":"Kong","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2026.117014_bib5","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/bjc.2017.357","article-title":"Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic review","volume":"117","author":"Prawira","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2026.117014_bib6","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1001\/jama.2023.20181","article-title":"Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial","volume":"330","author":"Mai","year":"2023","journal-title":"Jama"},{"key":"10.1016\/j.ejca.2026.117014_bib7","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","article-title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.117014_bib8","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","article-title":"Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)","volume":"41","author":"Yang","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2026.117014_bib9","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/hed.26999","article-title":"Definitive radiation therapy and liver local therapy in de novo liver metastatic nasopharyngeal carcinoma: Large cohort study","volume":"44","author":"Yang","year":"2022","journal-title":"Head & Neck"},{"key":"10.1016\/j.ejca.2026.117014_bib10","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.oraloncology.2019.03.015","article-title":"Effect of local treatment for metastasis and its sequence with chemotherapy on prognosis of post-treatment metastatic nasopharyngeal carcinoma patients","volume":"92","author":"Liang","year":"2019","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ejca.2026.117014_bib11","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrclinonc.2016.211","article-title":"Radiotherapy and immunotherapy: a beneficial liaison?","volume":"14","author":"Weichselbaum","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117014_bib12","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1158\/1078-0432.CCR-15-1352","article-title":"PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor","volume":"22","author":"Shi","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.117014_bib13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13014-022-02073-8","article-title":"Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent\/metastatic nasopharyngeal carcinoma","volume":"17","author":"Lin","year":"2022","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ejca.2026.117014_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003290","article-title":"Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trial","volume":"9","author":"Hua","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2026.117014_bib15","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1002\/ijc.32380","article-title":"Relationship of circulating tumor cells and Epstein-Barr virus DNA to progression-free survival and overall survival in metastatic nasopharyngeal carcinoma patients","volume":"145","author":"You","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2026.117014_bib16","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s12916-025-04103-0","article-title":"Nimotuzumab combined with docetaxel and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, phase 2 trial","volume":"23","author":"Zou","year":"2025","journal-title":"BMC Med"},{"key":"10.1016\/j.ejca.2026.117014_bib17","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1002\/hed.28219","article-title":"Current Trends in the Management of Recurrent Nasopharyngeal Carcinoma","volume":"47","author":"Pandrangi","year":"2025","journal-title":"Head & Neck"},{"key":"10.1016\/j.ejca.2026.117014_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.762663","article-title":"Is Immune Therapy Plus Chemotherapy More Effective Than Immune Therapy Alone for Unresectable Recurrent Nasopharyngeal Carcinoma?","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejca.2026.117014_bib19","doi-asserted-by":"crossref","first-page":"5506","DOI":"10.7150\/jca.98775","article-title":"PD-1 Inhibitors Combined with Chemotherapy versus Re-irradiation\/chemoradiotherapy for Unresectable Locally Recurrent T3-4 Nasopharyngeal Carcinoma: A Retrospective Study","volume":"15","author":"Liu","year":"2024","journal-title":"J Cancer"},{"key":"10.1016\/j.ejca.2026.117014_bib20","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1038\/s41588-025-02253-8","article-title":"Single-cell and spatial transcriptomics reveal mechanisms of radioresistance and immune escape in recurrent nasopharyngeal carcinoma","volume":"57","author":"You","year":"2025","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2026.117014_bib21","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1001\/jamaoncol.2020.1808","article-title":"Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial","volume":"6","author":"You","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.117014_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221112486","article-title":"Efficacy of local therapy to metastatic foci in nasopharyngeal carcinoma: large-cohort strictly-matched retrospective study","volume":"14","author":"Zhang","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejca.2026.117014_bib23","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.1016\/j.ejrad.2011.05.037","article-title":"Comparative survival analysis in patients with pulmonary metastases from nasopharyngeal carcinoma treated with radiofrequency ablation","volume":"81","author":"Pan","year":"2012","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.ejca.2026.117014_bib24","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1245\/s10434-021-09597-5","article-title":"Pulmonary Metastasectomy in Patients with Lung Metastases from Nasopharyngeal Carcinoma","volume":"28","author":"Zhao","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2026.117014_bib25","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1002\/hed.26706","article-title":"Local treatment of metastases plus systemic chemotherapy on overall survival of patients with metastatic nasopharyngeal carcinoma","volume":"43","author":"Liao","year":"2021","journal-title":"Head & Neck"},{"key":"10.1016\/j.ejca.2026.117014_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2024.106695","article-title":"A prospective, single-arm trial of PD-1 inhibitors plus chemoradiotherapy for solitary metachronous metastasis nasopharyngeal carcinoma","volume":"150","author":"Li","year":"2024","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ejca.2026.117014_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.6764","article-title":"Long-term outcomes of metastasis-directed stereotactic body radiation therapy in metastatic nasopharyngeal carcinoma","volume":"13","author":"Yang","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2026.117014_bib28","article-title":"Locoregional Radiotherapy Candidates in de Novo Metastatic Nasopharyngeal Carcinoma: Real-World Insights in the Immunotherapy Era","volume":"23:e247086","author":"Wen","year":"2025","journal-title":"Journal National Comprehensive Cancer Network JNCCN"},{"key":"10.1016\/j.ejca.2026.117014_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110687","article-title":"Efficacy of local-regional radiotherapy in de novo metastatic nasopharyngeal carcinoma patients receiving chemo-immunotherapy: A multicenter, propensity score matching study","volume":"203","author":"He","year":"2025","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.ejca.2026.117014_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2026.107907","article-title":"Efficacy of radiotherapy to metastatic lesion in de novo metastatic nasopharyngeal carcinoma patients: A multicenter, propensity score matching study","volume":"175","author":"Zhao","year":"2026","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ejca.2026.117014_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110265","article-title":"Long-term efficacy analysis of radiotherapy and local management of metastases in patients with newly diagnosed oligometastatic nasopharyngeal carcinoma: A prospective, single-arm, single-center clinical study","volume":"196","author":"Huang","year":"2024","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.ejca.2026.117014_bib32","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41571-018-0119-7","article-title":"Time to abandon single-site irradiation for inducing abscopal effects","volume":"16","author":"Brooks","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117014_bib33","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117014_bib34","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s00262-024-03905-0","article-title":"Metastatic sites of baseline as predictors in recurrent or metastatic nasopharyngeal carinoma treated with PD-L1 inhibitor: a secondary analysis of multicenter, single-arm, phase II study (KL-A167)","volume":"74","author":"Li","year":"2025","journal-title":"Cancer Immunology Immunotherapy CII"},{"key":"10.1016\/j.ejca.2026.117014_bib35","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ijc.35139","article-title":"Optimal therapeutic strategies for hepatic metachronous oligometastatic nasopharyngeal carcinoma: Insights from a retrospective study","volume":"156","author":"Huang","year":"2025","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2026.117014_bib36","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/jamaoncol.2023.1891","article-title":"Association Between Duration of Immunotherapy and Overall Survival in Advanced Non-Small Cell Lung Cancer","volume":"9","author":"Sun","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.117014_bib37","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.28526","article-title":"Overall Survival, Treatment Duration, and Rechallenge Outcomes With ICI Therapy for Recurrent or Metastatic HNSCC","volume":"7","author":"Sun","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejca.2026.117014_bib38","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/ijc.35382","article-title":"Efficacy and optimal duration of maintenance immunotherapy following systemic chemoimmunotherapy and locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A multicenter retrospective cohort study","volume":"157","author":"Hu","year":"2025","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2026.117014_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103434","article-title":"Rechallenge of immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"165","author":"Inno","year":"2021","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"10.1016\/j.ejca.2026.117014_bib40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00262-025-04258-y","article-title":"Efficacy and prognostic model development of immune checkpoint inhibitor rechallenge in recurrent or metastatic nasopharyngeal carcinoma: a real-world study","volume":"75","author":"Jiang","year":"2026","journal-title":"Cancer Immunology Immunotherapy CII"},{"key":"10.1016\/j.ejca.2026.117014_bib41","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2147\/CMAR.S460716","article-title":"Efficacy and Safety of Re-Challenging PD-1 Inhibitors in Second-Line Treatment in Metastatic Nasopharyngeal Carcinoma Previously Treated with Chemotherapy and PD-1 Inhibitors","volume":"16","author":"Bei","year":"2024","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ejca.2026.117014_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104113","article-title":"Anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment beyond progression in recurrent\/metastatic nasopharyngeal carcinoma patients","volume":"190","author":"Jiang","year":"2023","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"10.1016\/j.ejca.2026.117014_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103960","article-title":"Recursive partitioning analysis model for de novo metastatic nasopharyngeal carcinoma treated with locoregional radiotherapy following chemoimmunotherapy","volume":"9","author":"Wen","year":"2024","journal-title":"ESMO Open"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926007951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926007951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:34:23Z","timestamp":1790800463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926007951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":43,"alternative-id":["S0959804926007951"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117014","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Local therapy to recurrent\/metastatic foci augments the benefit of immune checkpoint inhibitors in nasopharyngeal carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117014"}}